Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document


Previous Fragment    Next Fragment

Notice given 3 October 2003

2182  Senator Bartlett: To ask the Minister for Defence—

(1) What were the top 200 Defence export approvals, by value, for the 1999-2000, 2000-01, 2001-02, and 2002-03 financial years.

(2) Which companies were involved in each of these contracts.

(3) To which countries did each of these approvals refer.

(4) What was the nature of the equipment involved in each contract.

(5) Given that the Stockholm International Peace Research Institute 2001 report found Australia to be the 14th largest exporter of arms in the world: What is the latest rating of Australia’s place in arms exporting.

2183  Senator Allison: To ask the Minister for Defence—With reference to the Director-General Defence Health Service Health Bulletin No 7/2003, 6 August 2003, which states ‘Screening for exposure to DU [depleted uranium] will be offered to those [personnel deployed to the Middle East Area of Operations] considered at increased risk and those who request it’:

(1) How many personnel, from what operations, and within which classification of exposure risk categories 1, 2 and 3, have been tested to date.

(2) Have any personnel been denied testing.

(3) How has the availability of testing been advertised to personnel, including those who have left the services.

(4) Is testing available to personnel who participated in the 1991 Gulf War; if so, how are they being informed of the availability of testing.

(5) Can a report of the results of testing for depleted uranium be provided.

2184  Senator Allison: To ask the Minister representing the Minister for Health and Ageing—

(1) Did the Intergovernmental Committee on Drugs establish a National Drug Research Committee to identify research needed to fill gaps in knowledge concerning the development of illicit drug policy.

(2) Has the National Drug Research Committee prepared a draft National Drug Research Strategy; if so: (a) when was it provided to the Minister; (b) what is the status of the strategy; and (c) what research does it propose.

(3) When is it expected that the Intergovernmental Committee on Drugs will meet to consider the draft National Drug Research Strategy.

(4) Has the Intergovernmental Committee on Drugs already decided not to endorse the draft National Drug Research Strategy; if so, why.

(5) Can the Minister table a copy of the draft National Drug Research Strategy; if not, why not.

(6) Does the Government accept that it is still possible for the operations of drug syndicates to be profitable even if they lose up to 90 per cent of their product to seizures.

(7) Has the Commonwealth commissioned research into the economic drivers of the illicit drug market; if not, does it plan to do so, and when.

(8) Has the Commonwealth commissioned research into the marketing strategies of drug syndicates; if not, does it plan to do so.